SUNNYVALE, Calif.--(BUSINESS WIRE)--CellMax Life, the precision cancer testing company, announced today the immediate availability in India of the CellMax-DNA Genetic Cancer Risk Test, which ...

SUNNYVALE, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- CellMax Life, a molecular diagnostics company, announced today that its FirstSight™ pre-cancer and cancer detection blood test has received ...

SUNNYVALE, Calif.--(BUSINESS WIRE)--CellMax Life, the precision cancer testing company, announced today the commercial availability of CellMax-LBx Liquid Biopsy in India. CellMax-LBx is a cancer ...

Data to be presented at ASCO Gastrointestinal Cancers Symposium The data from this prospective study showed that CellMax's FirstSight blood test demonstrated 92% sensitivity for colorectal cancer ...

Sunnyvale, California-based CellMax Life said Tuesday it was granted the patents for its CMx biomimetic platform, which is designed to detect circulating tumor cells (CTCs) in the blood.

CellMax Life has earned $9 million in Series A-1 venture funding, bringing their total funding to $14 million. The company aims to “fundamentally transform cancer care,” it said, using its ...

Results from a single-center study of CellMax Life's FirstSight blood test were released as a poster as part of the annual Digestive Disease Week ®, which was canceled because of COVID-19.

A study by CellMax Life found that the company's blood-based test was able to detect the small, precancerous colon polyps known as adenomas with close to 90% accuracy. By filtering out and ...